Current pharmacological concepts for wise use of echinocandins in the treatment of Candida infections in septic critically ill patients

Expert Review of Anti-Infective Therapy

Volumn 11, Issue 10, 2013, Pages 989-997

  Pea, Federico ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

candidemia; candidiasis; clinical pharmacology; critically ills; echinocandins

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; DICLOFENAC; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; MICAFUNGIN; NONSTEROID ANTIINFLAMMATORY AGENT; VORICONAZOLE;

ADD ON THERAPY; ANTI BIOFILM ACTIVITY; ANTIFUNGAL ACTIVITY; CANDIDEMIA; CANDIDIASIS; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG EFFICACY; DRUG METABOLISM; DRUG USE; EMPYEMA; FUNGAL ENDOCARDITIS; FUNGAL ENDOPHTHALMITIS; FUNGICIDAL ACTIVITY; HUMAN; MONOTHERAPY; NONHUMAN; PERITONITIS; REVIEW; SEPTIC SHOCK;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; CRITICAL ILLNESS; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; DRUG THERAPY, COMBINATION; ECHINOCANDINS; HUMANS; PRACTICE GUIDELINES AS TOPIC; PYRIMIDINES; SEPSIS; TRIAZOLES;

EID: 84886930971     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2013.836058     Document Type: Review

References (63)

1. Lepak A, Andes D. Fungal sepsis: optimizing antifungal therapy in the critical care setting. Crit. Care Clin. 27(1), 123-147 (2011).
2. Kollef M, Micek S, Hampton N, Doherty JA, Kumar A. Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin. Infect. Dis. 54(12), 1739-1746 (2012).
3. Vazquez JA. Invasive fungal infections in the intensive care unit. Semin. Respir. Crit. Care Med. 31(1), 79-86 (2010).
4. Pappas PG, Kauffman CA, Andes D et al Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48(5), 503-535 (2009).
5. Cornely OA, Bassetti M, Calandra T et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin. Microbiol. Infect. 18(Suppl. 18), 19-37 (2012).
6. Krishnan-Natesan S, Manavathu EK, Cutright JL, Chandrasekar PH. Efficacy of anidulafungin, caspofungin and fluconazole in the early phase of infection in a neutropenic murine invasive candidiasis model. Int. J. Antimicrob. Agents 36(1), 33-36 (2010).
7. Ortega M, Marco F, Soriano A et al Candida spp. bloodstream infection: influence of antifungal treatment on outcome.J. Antimicrob. Chemother. 65(3), 562-568 (2010).
8. Reboli AC, Rotstein C, Pappas PG et al Anidulafungin versus fluconazole for invasive candidiasis. N. Engl. J. Med. 356(24), 2472-2482 (2007).
9. Kett DH, Shorr AF, Reboli AC, Reisman AL, Biswas P, Schlamm HT. Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis. Crit. Care 15(5), R253 (2011).
10. Andes DR, Safdar N, Baddley JW et al Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin. Infect. Dis. 54(8), 1110-1122 (2012).
11. Hsu DI, Nguyen M, Nguyen L, Law A, Wong-Beringer A. A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients. J. Antimicrob. Chemother. 65(8), 1765-1770 (2010).
12. Pannanusorn S, Fernandez V, Romling U. Prevalence of biofilm formation in clinical isolates of Candida species causing bloodstream infection. Mycoses 56(3), 264-272 (2013).
13. Katragkou A, Chatzimoschou A, Simitsopoulou M et al. Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms. Antimicrob. Agents Chemother. 52(1), 357-360 (2008).
14. Nett JE, Sanchez H, Cain MT, Andes DR Genetic basis of Candida biofilm resistance due to drug-sequestering matrix glucan. J. Infect. Dis. 202(1), 171-175 (2010).
15. Nucci M, Anaissie E, Betts RF et al. Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials. Clin. Infect. Dis. 51(3), 295-303 (2010).
16. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob. Agents Chemother. 46(6), 1773-1780 (2002).
17. Ramage G, Jose A, Sherry L, Lappin DF, Jones B, Williams C. Liposomal amphotericin B displays rapid dose-dependent activity against Candida albicans biofilms. Antimicrob. Agents Chemother. 57(5), 2369-2371 (2013).
18. Bink A, Kucharikova S, Neirinck B et al The nonsteroidal antiinflammatory drug diclofenac potentiates the in vivo activity of caspofungin against Candida albicans biofilms.J. Infect. Dis. 206(11), 1790-1797 (2012).
19. Scaravilli V, Tinchero G, Citerio G, Participants in the International Multi-Disciplinary Consensus Conference on the Critical Care Management of Subarachnoid H. Fever management in SAH. Neurocrit. Care 15(2), 287-294 (2011).
20. Cormio M, Citerio G. Continuous low dose diclofenac sodium infusion to control fever in neurosurgical critical care. Neurocrit. Care 6(2), 82-89 (2007).
21. Mean M, Marchetti O, Calandra T. Bench-to-bedside review: Candida infections in the intensive care unit. Crit. Care 12(1), 204 (2008).
22. Garnacho-Montero J, Diaz-Martin A, Garcia-Cabrera E et al. Risk factors for fluconazole-resistant candidemia. Antimicrob. Agents Chemother. 54(8), 3149-3154 (2010).
23. Rautemaa R, Richardson M, Pfaller MA, Perheentupa J, Saxen H. Activity of amphotericin B, anidulafungin, caspofungin, micafungin, posaconazole, and voriconazole against Candida albicans with decreased susceptibility to fluconazole from APECED patients on long-term azole treatment of chronic mucocutaneous candidiasis. Diagn. Microbiol. Infect. Dis. 62(2), 182-185 (2008).
24. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348(2), 138-150 (2003).
25. Wang H, Ma S. The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome. Am. J. Emerg. Med. 26(6), 711-715 (2008).
26. Baltch AL, Lawrence DA, Ritz WJ et al. Effects of echinocandins on cytokine/chemokine production by human monocytes activated by infection with Candida glabrata or by lipopolysaccharide. Diagn. Microbiol. Infect. Dis 72(3), 226-233 (2012).
27. Baltch AL, Lawrence D, Ritz WJ et al. Effects of anidulafungin and voriconazole, singly and in combination, on cytokine/chemokine production by human monocyte-derived macrophages infected with Candida glabrata or activated by lipopolysaccharide. Chemotherapy 58(2), 146-151 (2012).
28. Wheeler RT, Fink GR. A drug-sensitive genetic network masks fungi from the immune system. PLoS Pathog. 2(4), e35 (2006).
29. Ben-Ami R, Lewis RE, Kontoyiannis DP. Immunocompromised hosts: immunopharmacology of modern antifungals. Clin. Infect. Dis. 47(2), 226-235 (2008).
30. Bal AM. The echinocandins: three useful choices or three too many? Int. J. Antimicrob. Agents 35(1), 13-18 (2010).
31. Andes D, Diekema DJ, Pfaller MA, Bohrmuller J, Marchillo K, Lepak A. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob. Agents Chemother. 54(6), 2497-2506 (2010).
32. Spreghini E, Orlando F, Sanguinetti M et al Comparative effects of micafungin, caspofungin, and anidulafungin against a difficult-to-treat fungal opportunistic pathogen, Candida glabrata. Antimicrob. Agents Chemother. 56(3), 1215-1222 (2012).
33. Spreghini E, Orlando F, Tavanti A et al. In vitro and in vivo effects of echinocandins against Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis. J. Antimicrob. Chemother. 67(9), 2195-2202 (2012).
34. Chen SC, Slavin MA, Sorrell TC. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs 71(1), 11-41 (2011).
35. Nguyen TH, Hoppe-Tichy T, Geiss HK et al. Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit. J. Antimicrob. Chemother. 60(1), 100-106 (2007).
36. European Medicines Agency. Cancidas, Summary of product charcteristics. Electronic Medicines Compendium (eMC), Datapharm Communications Ltd (2012).
37. Jullien V, Blanchet B, Benyamina M, Tod M, Vinsonneau C. Pharmacokinetics of caspofungin in two patients with burn injuries. Antimicrob. Agents Chemother. 56(8), 4550-4551 (2012).
38. Liu P, Ruhnke M, Meersseman W, Paiva JA, Kantecki M, Damle B. Pharmacokinetics of anidulafungin in critically ill patients with candidemia/invasive candidiasis. Antimicrob. Agents Chemother. 57(4), 1672-1676 (2013).
39. Stern JB, Girard P, Caliandro R. Pleural diffusion of voriconazole in a patient with Aspergillus fumigatus empyema thoracis. Antimicrob. Agents Chemother. 48(3), 1065 (2004).
40. Moriyama B, Torabi-Parizi P, Pratt AK et al. Pharmacokinetics of liposomal amphotericin B in pleural fluid. Antimicrob. Agents Chemother. 54(4), 1633-1635 (2010).
41. Carneiro HA, Mavrakis A, Mylonakis E. Candida peritonitis: an update on the latest research and treatments. World J. Surg. 35(12), 2650-2659 (2011).
42. Tobudic S, Forstner C, Schranz H, Poeppl W, Vychytil A, Burgmann H. Comparative in vitro fungicidal activity of echinocandins against Candida albicans in peritoneal dialysis fluids. Mycoses doi:10.1111/myc.12079 (2013) (Epub ahead of print).
43. Buijk SL, Gyssens IC, Mouton JW, Verbrugh HA, Touw DJ, Bruining HA. Pharmacokinetics of sequential intravenous and enteral fluconazole in critically ill surgical patients with invasive mycoses and compromised gastro-intestinal function. Intensive Care Med. 27(1), 115-121 (2001).
44. Peng LW, Lien YH. Pharmacokinetics of single, oral-dose voriconazole in peritoneal dialysis patients. Am. J. Kidney Dis. 45(1), 162-166 (2005).
45. Bor DH, Woolhandler S, Nardin R, Brusch J, Himmelstein DU. Infective endocarditis in the U.S., 1998-2009: a nationwide study. PLoS ONE 8(3), e60033 (2013).
46. Pai MP. Antifungal combinations against simulated Candida albicans endocardial vegetations. Antimicrob. Agents. Chemother. 53(6), 2629-2631 (2009).
47. Nagao M, Saito T, Doi S et al. Clinical characteristics and risk factors of ocular candidiasis. Diagn. Microbiol. Infect. Dis. 73(2), 149-152 (2012).
48. Riddell Jt, Comer GM, Kauffman CA. Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents. Clin. Infect. Dis. 52(5), 648-653 (2011).
49. Goldblum D, Fausch K, Frueh BE, Theurillat R, Thormann W, Zimmerli S. Ocular penetration of caspofungin in a rabbit uveitis model. Graefes Arch. Clin. Exp. Ophthalmol. 245(6), 825-833 (2007).
50. Gauthier GM, Nork TM, Prince R, Andes D. Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis. Clin. Infect. Dis. 41(3), e27-e28 (2005).
51. Mochizuki K, Sawada A, Suemori S et al. Intraocular penetration of intravenous micafungin in inflamed human eyes. Antimicrob. Agents. Chemother. 57(8), 4027-4030 (2013).
52. Mian UK, Mayers M, Garg Y et al. Comparison of fluconazole pharmacokinetics in serum, aqueous humor, vitreous humor, and cerebrospinal fluid following a single dose and at steady state. J. Ocul. Pharmacol. Ther. 14(5), 459-471 (1998).
53. Hariprasad SM, Mieler WF, Holz ER et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch. Ophthalmol. 122(1), 42-47 (2004).
54. Hariprasad SM, Mieler WF, Lin TK, Sponsel WE, Graybill JR. Voriconazole in the treatment of fungal eye infections: a review of current literature. Br. J. Ophthalmol. 92(7), 871-878 (2008).
55. Goldblum D, Rohrer K, Frueh BE, Theurillat R, Thormann W, Zimmerli S. Ocular distribution of intravenously administered lipid formulations of amphotericin B in a rabbit model. Antimicrob. Agents Chemother. 46(12), 3719-3723 (2002).
56. Spriet I, Delaere L, Lagrou K, Peetermans WE, Maertens J, Willems L. Intraocular penetration of voriconazole and caspofungin in a patient with fungal endophthalmitis. J. Antimicrob. Chemother. 64(4), 877-878 (2009).
57. Kauffman CA, Fisher JF, Sobel JD, Newman CA. Candida urinary tract infections-diagnosis. Clin. Infect. Dis. 52 (Suppl. 52), S452-S456 (2011).
58. Kofteridis DP, Papadimitraki E, Mantadakis E et al. Effect of diabetes mellitus on the clinical and microbiological features of hospitalized elderly patients with acute pyelonephritis. J. Am. Geriatr. Soc. 57(11), 2125-2128 (2009).
59. Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob. Agents Chemother. 46(3), 834-840 (2002).
60. Alexander BD, Johnson MD, Pfeiffer CD et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin. Infect. Dis. 56(12), 1724-1732 (2013).
61. Beyda ND, Lewis RE, Garey KW. Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches. Ann. Pharmacother. 46(7-8), 1086-1096 (2012).
62. Pfaller MA, Diekema DJ, Andes D et al. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist. Updat. 14(3), 164-176 (2011).
63. Arendrup MC, Rodriguez-Tudela J-L, Park S et al. Echinocandin susceptibility testing of Candida spp. Using EUCAST EDef 7.1 and CLSI M27-A3 standard procedures: analysis of the influence of bovine serum albumin supplementation, storage time, and drug lots. Antimicrob. Agents. Chemother. 55(4), 1580-1587 (2011).